Clearstead Advisors, LLC Eliem Therapeutics, Inc. Transaction History
Clearstead Advisors, LLC
- $6.94 Billion
- Q2 2025
A detailed history of Clearstead Advisors, LLC transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 11 shares of ELYM stock, worth $45. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11Holding current value
$45% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ELYM
# of Institutions
68Shares Held
49.5MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.82% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2.5MShares$10.3 Million0.01% of portfolio
-
Citigroup Inc1.61MShares$6.62 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.33MShares$5.47 Million0.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...